Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotes.

We previously demonstrated that integrin beta(3) Leu33Pro homozygotes have an increased risk of cancer, possibly most pronounced for ovarian cancer. We now test the latter hypothesis in case-control and prospective studies. We genotyped 463 Danish women with ovarian cancer, and 4291 women from the Danish general population. Calculation of odds ratios by conditional logistic regression was performed in the case-control study (n = 463 + 3543), and of ovarian cancer incidence, log-rank statistics and hazard ratios by Cox regression in the prospective study (n = 4291) with 9.5-year follow-up. In the case-control study matched for age and marital status, the odds ratio for ovarian cancer in homozygotes versus non-carriers was 1.6 (95% confidence interval: 1.0-2.6). In the prospective study with 28 incident ovarian cancers, non-carriers and homozygotes had incidences of 7 (4-11) and 30 (10-92) per 10 000 person-years (log-rank P = 0.02). The age-adjusted hazard ratio for ovarian cancer in homozygotes versus non-carriers was 3.9 (1.1-13). Risk of ovarian cancer did not differ between heterozygotes and non-carriers in either study. Integrin beta(3) Leu33Pro homozygotes have an increased risk of ovarian cancer.

[1]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  D. Cramer,et al.  Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. , 2005, Cancer research.

[3]  J. Chang-Claude,et al.  Re: Integrin β3 Leu33Pro Homozygosity and Risk of Cancer , 2005 .

[4]  D. Monos,et al.  Identification of HLA-DQα and -DRβ residues associated with susceptibility and protection to epithelial ovarian cancer , 2005 .

[5]  D. Monos,et al.  Identification of HLA-DQalpha and -DRbeta residues associated with susceptibility and protection to epithelial ovarian cancer. , 2005, Human immunology.

[6]  D. Edwards,et al.  A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. , 2004, The Journal of clinical endocrinology and metabolism.

[7]  B. Thomsen,et al.  Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. , 2004, Archives of internal medicine.

[8]  A. Whittemore,et al.  STK15 polymorphisms and association with risk of invasive ovarian cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  G. Kundu,et al.  Nuclear Factor-inducing Kinase Plays a Crucial Role in Osteopontin-induced MAPK/IκBα Kinase-dependent Nuclear Factor κB-mediated Promatrix Metalloproteinase-9 Activation* , 2004, Journal of Biological Chemistry.

[10]  T. Agorastos,et al.  P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women , 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[11]  Samuel C. Mok,et al.  Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer , 2004, Clinical Cancer Research.

[12]  A. Harris,et al.  Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. , 2004, Gynecologic oncology.

[13]  S. Bojesen,et al.  RESPONSE: Re: Integrin β3 Leu33Pro Homozygosity and Risk of Cancer , 2004 .

[14]  K. Hemminki,et al.  Re: Integrin β3 Leu33Pro Homozygosity and Risk of Cancer , 2004 .

[15]  S. Ebrahim,et al.  Mendelian randomization: prospects, potentials, and limitations. , 2004, International journal of epidemiology.

[16]  E. Trabetti,et al.  PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[17]  T. Yeatman,et al.  Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies , 2004, Clinical Cancer Research.

[18]  K. Hemminki,et al.  Re: Integrin beta3 Leu33Pro homozygosity and risk of cancer. , 2004, Journal of the National Cancer Institute.

[19]  G. Kundu,et al.  Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. , 2004, The Journal of biological chemistry.

[20]  R. Berkowitz,et al.  Osteopontin as an Adjunct to CA 125 in Detecting Recurrent Ovarian Cancer , 2004 .

[21]  S. Bojesen,et al.  Integrin β3 Leu33Pro Homozygosity and Risk of Cancer , 2003 .

[22]  S. Kjaer,et al.  Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study. , 2003, Anticancer research.

[23]  B. No̸rgaard-Pedersen,et al.  Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma , 2003, Cancer.

[24]  S. Dedhar,et al.  αv integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells , 2003, Oncogene.

[25]  Yan Liu,et al.  Enhanced Activation of Mitogen-activated Protein Kinase and Myosin Light Chain Kinase by the Pro33 Polymorphism of Integrin β3 * , 2003, The Journal of Biological Chemistry.

[26]  S. Dedhar,et al.  alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. , 2003, Oncogene.

[27]  G. Johnson,et al.  Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases , 2002, Science.

[28]  P. Bray,et al.  PlA Polymorphism of Integrin &bgr;3 Differentially Modulates Cellular Migration on Extracellular Matrix Proteins , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[29]  C. Watala,et al.  Polymorphisms of glycoprotein Ib affect the inhibition by aurintricarboxylic acid of the von Willebrand factor dependent platelet aggregation , 2002, Journal of Molecular Medicine.

[30]  D. Fishman,et al.  Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. , 2002, Cancer research.

[31]  B. Ponder,et al.  The genetics of ovarian cancer. , 2002, Best practice & research. Clinical obstetrics & gynaecology.

[32]  R. Berkowitz,et al.  Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.

[33]  David A. Cheresh,et al.  Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.

[34]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 1995. , 2002, European journal of cancer.

[35]  M. Mascelli,et al.  Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. , 2002, American heart journal.

[36]  J. Ostrowski,et al.  Peptide analog of fibronectin that inhibits cell migration and ERK 1/2 activity , 2001, Peptides.

[37]  G. FitzGerald,et al.  Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets. , 2001, Blood.

[38]  G. Gaetano,et al.  Platelet Glycoprotein Receptor IIIa Polymorphism PlA1/PlA2 and Coronary Risk: a Meta-Analysis , 2001, Thrombosis and Haemostasis.

[39]  J. Ferlay,et al.  Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .

[40]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[41]  P. Bray,et al.  The PlA2 polymorphism of integrin β3 enhances outside-in signaling and adhesive functions , 2000 .

[42]  M. Furman,et al.  Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. , 2000, Circulation.

[43]  B. Ponder,et al.  The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. , 1999, American journal of human genetics.

[44]  D. Levy,et al.  Increased Platelet Aggregability Associated With Platelet GPIIIa PlA2 Polymorphism : The Framingham Offspring Study , 1999 .

[45]  J. Rader,et al.  Expression of αvβ3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas , 1997 .

[46]  J. Rader,et al.  Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. , 1997, Human pathology.

[47]  J. Niloff,et al.  Expression and Function of 1 and av3 Integrins in Ovarian Cancer , 1995 .

[48]  J. Niloff,et al.  Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. , 1995, Gynecologic oncology.

[49]  E. Thomas,et al.  Expression of integrin adhesion molecules in normal ovary and epithelial ovarian tumors , 1993, International Journal of Gynecologic Cancer.

[50]  S. Lord,et al.  The genomic organization of platelet glycoprotein IIIa. , 1990, The Journal of biological chemistry.

[51]  M. Levin,et al.  The occurrence of lung cancer in man. , 1953, Acta - Unio Internationalis Contra Cancrum.